Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2022

View Archived Issues

Targeting secretogranin III induces antiangiogenic effect during choroidal neovascularization

Dual Kv7 channel/TPSO receptor activator GRT-X shows promise in a refractory seizure model

Betta Pharmaceuticals discovers CD73 inhibitors

New MET/MERTK/TRYO3/AXL inhibitors identified at Aucentra Therapeutics

New IL-17RA antagonists presented by Hitgen

Shanghai Institute of Materia Medica patents glucose-lowering agents

Chengdu Fanxi Biopharma identifies PPAR-alpha and/or PPAR-delta agonists

New antipsychotic shows partial agonist activity at DRD2/3 and 5-HT1AR with little 5-HT2AR binding

STI-1558 strongly inhibits Omicron variant in cell-based assays

ATH-434 demonstrates efficacy in preclinical multiple system atrophy

Design of a next-generation cell-based therapy against diabetes

Improved retinal transplants ready for clinical trials

IDE-161 enters IND-enabling studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...